X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CIPLA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CIPLA ASTRAZENECA PHARMA/
CIPLA
 
P/E (TTM) x 116.1 34.8 333.9% View Chart
P/BV x 22.5 3.1 714.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   CIPLA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
CIPLA
Mar-18
ASTRAZENECA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,278663 192.8%   
Low Rs883479 184.3%   
Sales per share (Unadj.) Rs228.4189.0 120.8%  
Earnings per share (Unadj.) Rs10.417.6 58.9%  
Cash flow per share (Unadj.) Rs16.334.0 47.8%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs98.8176.7 55.9%  
Shares outstanding (eoy) m25.00805.12 3.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.73.0 156.6%   
Avg P/E ratio x104.232.5 321.2%  
P/CF ratio (eoy) x66.416.8 395.9%  
Price / Book Value ratio x10.93.2 338.5%  
Dividend payout %017.1 0.0%   
Avg Mkt Cap Rs m27,008459,724 5.9%   
No. of employees `0001.423.6 5.7%   
Total wages/salary Rs m1,53526,901 5.7%   
Avg. sales/employee Rs Th4,210.96,446.1 65.3%   
Avg. wages/employee Rs Th1,132.21,139.4 99.4%   
Avg. net profit/employee Rs Th191.1600.0 31.8%   
INCOME DATA
Net Sales Rs m5,710152,193 3.8%  
Other income Rs m1233,577 3.4%   
Total revenues Rs m5,833155,769 3.7%   
Gross profit Rs m46328,264 1.6%  
Depreciation Rs m14713,228 1.1%   
Interest Rs m01,142 0.0%   
Profit before tax Rs m43817,470 2.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m1792,501 7.2%   
Profit after tax Rs m25914,166 1.8%  
Gross profit margin %8.118.6 43.7%  
Effective tax rate %40.814.3 285.3%   
Net profit margin %4.59.3 48.8%  
BALANCE SHEET DATA
Current assets Rs m3,209108,141 3.0%   
Current liabilities Rs m2,07038,322 5.4%   
Net working cap to sales %20.045.9 43.5%  
Current ratio x1.62.8 55.0%  
Inventory Days Days7297 74.6%  
Debtors Days Days3574 46.9%  
Net fixed assets Rs m790109,411 0.7%   
Share capital Rs m501,610 3.1%   
"Free" reserves Rs m2,419140,682 1.7%   
Net worth Rs m2,469142,292 1.7%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m4,605228,606 2.0%  
Interest coverage xNM16.3-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.7 186.2%   
Return on assets %5.66.7 84.0%  
Return on equity %10.510.0 105.4%  
Return on capital %17.710.0 178.2%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30051,691 0.6%   
Fx outflow Rs m2,01521,033 9.6%   
Net fx Rs m-1,71530,658 -5.6%   
CASH FLOW
From Operations Rs m8814,628 0.6%  
From Investments Rs m-94-8,540 1.1%  
From Financial Activity Rs mNA-3,855 0.0%  
Net Cashflow Rs m-62,431 -0.2%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 0.3 12.2 2.5%  
FIIs % 15.7 23.7 66.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 9.1 26.2 34.7%  
Shareholders   12,856 161,166 8.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex and Nifty Open at Record Highs; Modi Takes Early Lead(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.8% while the Hang Seng is down 1.2%.

Related Views on News

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 23, 2019 11:01 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS